AAV-IGF2 Gene Delivery for Mutant Huntingtin Aggregate Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Huntington's disease focus on alleviating symptoms rather than slowing degeneration or reversing neuronal damage caused by protein misfolding, and there is a lack of effective gene therapy approaches using IGF2 for this condition.
Innovation Solution
The use of adeno-associated viruses (AAV) expressing IGF2 or IGF2-HA to induce neuronal overexpression in the brain, particularly in the striatum and cortex, through local administration, to modulate the proteostasis network and reduce mutant huntingtin expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If allopathic therapies (antipsychotics and antidepressants) are used to diminish symptoms, then symptom relief is achieved, but the degeneration and neuronal damage are not slowed or reversed
Solution Approach 1:
The patent uses AAV vectors as intermediaries to deliver the IGF2 gene into neurons, where the expressed IGF2 protein acts as a mediator to restore proteostasis balance. This intermediary approach allows the therapeutic protein to directly counteract the toxic effects of mutant huntingtin and restore cellular function, rather than merely masking symptoms with psychoactive drugs.
Solution Approach 2:
The patent changes the biochemical parameter of IGF2 expression levels in affected neurons by introducing exogenous IGF2 gene therapy. This parameter change restores the altered proteostasis network and UPR signaling, fundamentally addressing the disease mechanism rather than just symptom management.
2Reliability
If IGF2 is delivered via gene therapy to achieve neuroprotective effects, then neuronal survival is improved, but the complexity of the treatment approach increases
Solution Approach 1:
The AAV vector system is designed to be self-replicating and self-sustaining within target neurons. Once delivered, the IGF2 gene is continuously expressed from the viral genome, providing long-term neuroprotective effects without requiring repeated administrations or complex delivery infrastructure.
Solution Approach 2:
The AAV vector serves multiple functions: it acts as the delivery vehicle for the IGF2 gene, provides continuous expression of the therapeutic protein, and targets specific neuronal populations through its natural tropism. This multi-functionality reduces the need for separate components in the treatment system.
3Measurement precision
If AAV vectors are used to deliver IGF2 gene, then targeted gene delivery is achieved, but the manufacturing and production complexity increases
Solution Approach 1:
The AAV vector system achieves local quality by targeting specific brain regions (striatum and cortex) affected by Huntington's disease. The viral tropism and localized injection approach ensure that IGF2 expression is concentrated in the most affected areas, maximizing therapeutic benefit while minimizing off-target effects.
Solution Approach 2:
The manufacturing process is segmented into modular steps: plasmid construction, viral transfection, purification, and quality control. This segmentation allows each step to be optimized and controlled independently, facilitating scalable production while maintaining vector quality and safety standards.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly decreases mutant huntingtin aggregates, enhances neuronal viability, and slows the progression of Huntington's disease, as demonstrated by reduced mHtt expression and improved motor symptoms in animal models.
Implementation Method 1
The use of adeno-associated viruses (AAV) expressing IGF2 or IGF2-HA to induce neuronal overexpression in the brain
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The invention relates to the expression of two molecules in viral vectors AAV/IGF2-HA and AAV/IGF2, the associated method and use thereof in the amelioration of protein misfolding-related diseases, such as Huntington's disease, as presented in the in vivo models in figure 11/19.